Ahmedaba-based Cadila Healthcare Limited (Zydus Cadila) on Tuesday informed that the company has received a tentative approval from the US FDA for Aripiprazole Orally Disintegrating Tablets in the strengths of 10 mg, 15 mg, 20 mg and 30 mg. The drug is an anti-psychotic medication used in the treatment of schizophrenia, a company statement informed. Cadila Healthcare shares closed at Rs 877.10 up by 0.82 per cent on the Bombay Stock Exchange (BSE) on Tuesday.